BioSpace News Archive

Byondis B.V. (formerly Synthon Biopharmaceuticals B.V.) is pleased to announce the appointment of Robbert Van Heekeren as chief financial officer. Mr. Van Heekeren will assume this role on September 1, operating out of Byondis’ headquarters in Nijmegen.

In a Phase 1 study in the U.S., at 7 days after a second dose of 30 μg, BNT162b2 elicited SARS-CoV-2–neutralizing geometric mean titers (GMTs) in younger adults (18-55 years of age) that were 3.8 times the GMT of a panel of 38 sera of SARS-CoV-2 convalescent patients, and in older adults (65-85 years of age) the vaccine candidate elicited a neutralizing GMT 1.6 times the GMT of the same panel, demonstrating strong immunogenicity in younger and older adult

Diagnosing respiratory illness associated with vaping has always been challenging. Adding the spread of COVID-19 and the many similarities in symptoms makes it even more difficult.

Dr. Rama Kondru, executive vice president, chief information officer and chief technology officer at Medidata, a Dassault Systèmes company, has been selected by PharmaVOICE magazine as one of 2020’s 100 Most Inspiring People in the life science industry.

Cognate BioServices, Inc. announced today the appointments of Timothy Moore and Steven Kasok as independent non-executive members of its Board of Directors. “We are excited to welcome Tim Moore and

Karmanos Specialty Pharmacy is pleased to announce that it has received full accreditation from the Utilization Review Accreditation Commission.

Nanodropper, Inc., a medical device company offering a first-of-its-kind eyedrop bottle adaptor that reduces eyedrop size, has been named the recipient of a Phase II Small Business Innovation Research contract with the United States Air Force.

The combination of SmartPharm’s Gene Mab™ gene-encoded in vivo expression system and Sorrento’s SARS-CoV-2 neutralizing antibodies may potentially provide longer-acting, single injection protection against COVID-19. Beyond COVID-19, the synergies between Sorrento’s proprietary fully human G-MAB ™ Antibody Library and SmartPharm’s Gene-Encoded Therapeutics (GET) Platform are expected to provide a vast product pipeline of novel, long-acting therapeutic proteins for a broad range of diseases,

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced an operational update and financial results for the quarter ended June 30, 2020 .

Cytocom, Inc. (Cytocom), a clinical-stage biopharmaceutical company developing novel immune modulating therapies based on proprietary platforms, today announced the company and Immune Therapeutics, Inc. (OTC: IMUN; Immune) have entered into an agreement to reacquire the emerging market rights to distribute and market its late-stage investigational drug candidates CYTO-201 and CYTO-401